Structural reforms to improve the competitiveness of the BGM business
First written in FY2022-Q2. 8 of 14 entries say "Restated". Latest entry: 2026-08-06.
No other company in this theme has enough history to compare yet.
- 2026-08-06AdvancedEarnings
「The business achieved a substantial increase in profit as a result of favorable foreign exchange effects, cost savings from structural reforms implemented to date, improved profitability associated with the transfer of the CGM business, and other factors.」
In Diabetes Management, cost savings from past structural reforms and improved profitability associated with the transfer of the CGM business contributed to a substantial increase in first-quarter profit. - FY2026AdvancedAnnual report
「The BGM business achieved a substantial increase in profit as a result of solid sales in developed countries, improved margins from profitability improvements and pricing initiatives, cost savings from structural reforms implemented to date, lower depreciation and amortization, and improved profitability associated with the transfer of the CGM business.」
In the BGM business, higher unit prices, revenue enhancement and cost reductions from previous restructuring led to improved full-year margins and a substantial increase in profit. Operating profit in diabetes management increased 44.6% year on year to ¥20,085 million. - 2026-05-13AdvancedEarnings
「The BGM business achieved a substantial increase in profit as a result of solid sales in developed countries, improved margins from profitability improvements and pricing initiatives, cost savings from structural reforms implemented to date, lower depreciation and amortization, and improved profitability associated with the transfer of the CGM business.」
In the BGM business, cost savings from structural reforms, pricing initiatives, and profitability improvements associated with the transfer of the CGM business were reflected in a substantial increase in full-year profit. - FY2026-H1AdvancedAnnual report
「Profit increased substantially, supported by strong performance in the BGM business in developed countries, margin improvement from revenue-enhancement and unit-price improvement measures, the cost-saving effects of previous restructuring, and lower depreciation and amortization expenses, among other factors.」
In the BGM business, the effects of revenue enhancement, unit-price improvement and cost reductions, in addition to the previous organizational review and restructuring, emerged as improved margins and a substantial increase in profit. - FY2025AdvancedAnnual report
「The pathology business posted higher profit as a result of increased revenue, cost-reduction measures such as lower transportation costs, and improved margins supported by the effects of past organizational streamlining, among other factors.」
The effects of organizational streamlining and cost reductions were cited as drivers of improved margins in the pathology business, indicating that the effects of previous restructuring measures are being reflected in performance. - FY2024RestatedAnnual report
「Recording of ¥5,081 million in business restructuring-related expenses associated with reviewing the organizational structures of the BGM and diagnostic reagents businesses, among other measures.」
The review of the BGM business's organizational structure was extended to the diagnostic reagents business, and business restructuring-related expenses were recorded again for the current period. - FY2024-Q3RestatedAnnual report
「This was mainly due to the impact of the aforementioned decline in BGM business revenue, the recognition of ¥3,031 million in costs related to structural reform associated with reviewing the organizational structures of the BGM and diagnostics businesses, and increased selling expenses accompanying the expansion of the CGM business's sales organization.」
The company continued to review the organizational structure of the BGM business and expand the CGM sales structure, recording ¥3,031 million in business restructuring-related expenses. - FY2024-Q2RestatedAnnual report
「Recognition of ¥2,971 million in costs related to structural reform accompanying a review of the BGM business's organizational structure」
The company continued to review the BGM organizational structure and pursue structural reform, recognizing ¥2,971 million in related costs in the current period as well. - FY2024-Q1RestatedAnnual report
「In addition to recognizing ¥1,401 million in costs related to structural reform, mainly associated with reviewing the BGM organizational structure, increased selling expenses from expanding the CGM sales organization also became a factor behind the decline in profit.」
The company continued to review the BGM organizational structure and expand the CGM sales organization, and recognized ¥1,401 million in costs related to BGM structural reform. - FY2023-Q3RestatedAnnual report
「The company incurred ¥2,883 million in costs related to structural reform to review the BGM business's sales organization as a nonrecurring expense in the same period of the previous year.」
The company continued to review the BGM sales organization, and related costs in the current period were ¥118 million. - FY2023-Q2RestatedAnnual report
「Although the company worked to reduce selling expenses for BGM, selling, general and administrative expenses increased due to the strengthening of the CGM sales organization and foreign exchange effects.」
The company continued to reduce BGM selling expenses and strengthen the CGM sales organization. - FY2023-Q1RestatedAnnual report
「In addition to strengthening the CGM sales organization and working to reduce selling expenses, the company incurred ¥1,810 million in costs related to structural reform to review the BGM business's sales organization as a nonrecurring item in the same period of the previous year.」
The company continued to strengthen the CGM sales organization, reduce selling expenses, and review the BGM sales organization. - FY2022-Q3RestatedAnnual report
「This was mainly because Ascensia Diabetes Care Holdings AG, a consolidated subsidiary in the Diabetes Management segment, had begun initiatives at the company and its subsidiaries to improve the competitiveness of the blood glucose monitoring (BGM) system business.」
The company recognized ¥2,883 million in structural reform costs associated with reviewing the BGM business's sales organization and continued its structural reform. - FY2022-Q2First statedAnnual report
「This was mainly because Ascensia Diabetes Care Holdings AG, a consolidated subsidiary in the Diabetes Management segment, had begun initiatives at the company and its subsidiaries to improve the competitiveness of the blood glucose monitoring (BGM) system business.」
The company began restructuring, including a review of the BGM business's sales organization, to improve competitiveness.